Abstract: The present disclosure relates to antibodies that selectively bind to CD3 and its isoforms and homologs, and compositions comprising the antibodies. Also provided are methods of using the antibodies, such as therapeutic and diagnostic methods.

Abstract: A polypeptide complex comprises antibody variable regions of the heavy chain and light chain respectively fused to TCR constant regions. A bispecific antigen binding polypeptide complex contains a first antigen-binding moiety of the polypeptide complex and a second antigen-binding moiety. A method comprises producing the polypeptide complex of the bispecific antigen binding polypeptide complex. A method of treating disease or disorder comprises using the polypeptide complex or the bispecific antigen binding polypeptide complex. A polynucleotide encodes the polypeptide complex and/or the bispecific antigen binding polypeptide complex. A vector or a host cell contains the polynucleotide. A composition and a pharmaceutical composition comprise the polypeptide complex and/or the bispecific antigen binding polypeptide complex.

Abstract: The present disclosure provides a fusion protein, comprising an anti-PD-L1 single domain antibody fragment, an anti-VEGF fragment, and a TGF-? binding fragment. The multi-domain fusion protein with an anticancer activity combines the functions of the anti-PDL1 monoclonal antibody, the anti-VEGF monoclonal antibody, and the TGF-? receptor, where the anti-PDL1 monoclonal antibody blocks the PD-L1/PD-1 interaction, the anti-VEGF monoclonal antibody inhibits microvascular growth and metastatic disease, and the TGF-? receptor relieves cancer cells from TGF-? signal tolerance and enhances immune response. The fusion protein molecule provided by the present disclosure has an excellent effect on tumor treatment.

Abstract: Provided herein are methods and compositions for enhancing an immune response and/or for the treatment of an immune-related condition in an individual, comprising disabling myeloid cells using an anti-Triggering Receptor Expressed on Myeloid Cells 1 (TREM1) antibody.

Abstract: This disclosure provides a method for treating a subject afflicted with a urothelial carcinoma or cancer derived therefrom, which method comprises administering to the subject an antibody or an antigen-binding portion thereof that specifically binds to a Programmed Death-1 (PD-1) receptor and inhibits PD-1 activity or the combination of (a) an antibody or an antigen-binding portion thereof that specifically binds to a PD-1 receptor and inhibits PD-1 activity; and (b) an antibody or an antigen-binding portion thereof that specifically binds to a Cytotoxic T-Lymphocyte Antigen-4 (CTLA-4) and inhibits CTLA-4 activity.

Abstract: Provided herein are antibody molecules that bind specifically to Programmed cell death 1 (PD1) and related nucleic acid molecules, vectors and host cells. Also provided herein are medical uses of such antibody molecules.

Abstract: Antibodies that specifically bind to CD47 and antibodies that specifically bind to PD-L1 are provided, as well as CD47/PD-L1 bispecific antibodies. Also provided are uses of these antibodies, and related compositions and methods.

Abstract: This disclosure provides a method for treating HPV-positive squamous cell carcinoma of the head and neck comprising administering to the subject an immune checkpoint inhibitor, e.g., an anti-PD-1 antibody or an anti-PD-L1 antibody. The disclosure also provides a method for treating HPV-negative squamous cell carcinoma of the head and neck administering to the subject an immune checkpoint inhibitor, e.g., an anti-PD-1 antibody or an anti-PD-L1 antibody. The subject can be additionally administered another anti-cancer agent.

Abstract: The disclosure relates to antibodies that bind FcRn and methods of using these antibodies.

Abstract: The present invention relates to systems, kits, and methods for treating a subject that has cardiovascular disease or Systemic Sclerosis with at least one of the following: a) IgG3 ?1-Adrenergic Receptor antibodies (IgG3 ?1AR antibodies), or antigen-binding portion thereof; b) an antigenic protein that elicits the production of IgG3 ?1AR antibodies in the subject; or c) a vector comprising a nucleic acid sequence encoding the antigenic protein or IgG3 ?1AR antibodies. In certain embodiments, the subject has dilated cardiomyopathy. In some embodiments, the subject is also administered a beta-blocker.

Abstract: The disclosure relates to antibodies that bind human, murine, and canine IGF2R, and methods of using said antibodies. Provided herein are antibodies having specific CDRs identified herein, including functional variants of specific variable domains and IgGs having the specified CDR sequences, and immunoconjugates of said antibodies and uses thereof. Also provided herein are compositions and kits comprising said antibodies, and methods and uses of said antibodies, immunoconjugates, compositions, and kits. Also provided herein are the use of said antibodies for radioimmunotherapy (RIT) for cancer including osteosarcoma.

Abstract: Binding members for alpha chain of receptor for granulocyte macrophage colony stimulating factor (GM-CSFR?), especially antibody molecules. Use of the binding members in treating inflammatory and autoimmune diseases, e.g. rheumatoid arthritis, asthma, allergic response, multiple sclerosis, myeloid leukaemia and atherosclerosis.

Abstract: The disclosure provides for antibodies that bind CD40, including a humanized antibody. The antibodies bind CD40 and do not exhibit CD40 agonist activity. The antibodies may comprise a modified IgG1 Fc domain, and exhibit minimal activation of immature dendritic cells. Compositions comprising antibodies, methods of use for treatment of diseases involving CD40 activity, and use in the preparation of a medicament for treatment of a disease involving CD40 activity are provided.

Abstract: Antibodies, fragments thereof, and chimeric proteins comprising same are presented that have specific binding activity against CD30. Advantageously, contemplated molecules can be used in pharmaceutical compositions for immune therapy, particularly in individuals diagnosed with hematopoietic malignancies, including Hodgkin lymphoma, CD30-positive B cell lymphomas, CD30-positive T cell lymphomas, CD30-positive NK cell lymphomas.

Abstract: Anti-BCMA heavy chain-only antibodies (UniAb) and disclosed, along with methods of making such antibodies, compositions, including pharmaceutical compositions, comprising such antibodies, and their use to treat B-cell disorders characterized by the expression of BCMA.

Abstract: Disclosed herein are polynucleic acid molecules, pharmaceutical compositions, and methods for treating facioscapulohumeral muscular dystrophy (FSHD).

Abstract: Provided herein are anti-CD20 antibodies and uses thereof for treatment and diagnosis. Also provided are CD20 antigens for the production of anti-CD20 antibodies and methods of generating anti-CD20 antibodies using the CD20 antigens.

Abstract: Provided herein are anti-CD20 antibodies and uses thereof for treatment and diagnosis. Also provided are CD20 antigens for the production of anti-CD20 antibodies and methods of generating anti-CD20 antibodies using the CD20 antigens.

Abstract: The present invention concerns methods for treating progressive multiple sclerosis (MS) in a patient, and an article of manufacture with instructions for such use.

Abstract: Provided herein, in one aspect, are antibodies that immunospecifically bind to PSGL-1, polynucleotides comprising nucleotide sequences encoding such antibodies, and expression vectors and host cells for producing such antibodies. Also provided herein are kits and pharmaceutical compositions comprising antibodies that specifically bind to PSGL-1, as well as methods of treating a disorder or disease caused by or associated with increased proliferation and/or numbers of activated T cells using the antibodies described herein.

Abstract: Provided herein are D domain containing polypeptides that specifically bind targets of interest, as are nucleic acids encoding the D domain containing polypeptides, vectors containing the nucleic acids and host cells containing the nucleic acids and vectors. Also provided herein are methods of making and using the D domain containing polypeptides, nucleic acids, vectors and host cells, for example, but not limited to, in diagnostic and therapeutic applications. Also provided herein are multi-functional chimeric antigen receptor (CAR)-based compositions and Adapters and their use in methods of directing immune responses to target cells. In some embodiments, the methods include the use of a CAR expressing cell in combination with an Adapter. The Adapter confers the ability to modulate, alter, and/or direct CAR expressing cell-mediated immune response in vitro and in vivo.

Abstract: Provided herein are monoclonal antibodies (mAbs) that bind to human Cluster of Differentiation 73 (CD73). In particular, anti-CD73 mAbs are provided that bind to and inhibit the activity of human CD73.

Abstract: Multi-specific binding proteins that bind NKG2D, CD16, and CEACAM5 are described, as well as pharmaceutical compositions and therapeutic methods useful for the treatment of cancer

Abstract: This document relates to methods and materials for treating T cell cancers. For example, a composition containing one or more bispecific molecules targeting T cell receptor £ chain constant region (TRBC) can be administered to a mammal having a T cell cancer to treat the mammal. For example, this document provides methods and materials for using one or more bispecific molecules to treat a mammal having a T cell cancer.

Abstract: The present invention provides compositions for the production of an antibody or functional fragment thereof directed against disialoganglioside-GD2. The compositions of the invention include polynucleotides encoding a heavy chain and/or a light chain variable domain that binds to GD2. The invention also provides an isolated antibody or functional fragment thereof and methods of treating or preventing a disease, such as cancer or tumor formation, wherein the antibody or functional fragment includes a variable heavy chain domain and a variable light chain domain that has an amino acid sequence provided herein. The invention further provides a conjugate of an antibody or functional fragment thereof conjugated or recombinantly fused to a diagnostic agent, detectable agent or therapeutic agent, and methods of treating, preventing or diagnosing a disease in a subject in need thereof.

Abstract: The present disclosure provides methods for treating a subject having a HER2 non-amplified (HER2-negative) cancer or low HER2 expressing (HER2-low) cancer, comprising detecting expression of a BCAR4 gene fusion in a biological sample from the subject. If expression of the BCAR4 gene fusion is detected, a HER2-targeted cancer treatment is administered to the subject; if expression of the BCAR4 gene fusion is not detected, a cancer treatment that is not HER2-targeted is administered to the subject. Methods of predicting response to a HER2-targeted cancer treatment and detecting BCAR4 or BCAR4 gene fusion activation are also provided.

Abstract: In one aspect, the invention provides methods of inhibiting the effects of MASP-2-dependent complement activation in a living subject suffering from, or at risk for developing a thrombotic microangiopathy (TMA). The methods comprise the step of administering, to a subject in need thereof, an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation. In some embodiments, the MASP-2 inhibitory agent inhibits cellular injury associated with MASP-2-mediated alternative complement pathway activation, while leaving the classical (C1q-dependent) pathway component of the immune system intact.

Abstract: The present invention provides molecules, including proteins, more particularly, immunoglobulins whose in vivo half-lives are altered (increased or decreased) by the presence of an IgG constant domain, or FcRn binding fragment thereof (e.g., an Fc region or hinge-Fe region) (e.g., from a human IgG, e.g., human IgG1), that have modifications of one or more of amino acid residues in at least the CH3 domain.

Abstract: Methods for making, identifying, isolating and/or making binding proteins that contain an immunoglobulin light chain variable domain, including a somatically hypermutated light chain variable domain, fused with a heavy chain constant region, are provided. Exemplary binding proteins specific to small molecules are also provided.

Abstract: The present invention provides an antigen-binding molecule (e.g. antibody) with improved cytosol-penetrating ability, the molecule comprising an amino acid substitutions on at least one selected from the group consisting of CDRL1, CDRL2 and CDRL3 in a light-chain variable region, or an antigen-binding fragment (antibody fragment) thereof; and pharmaceutical compositions comprising the antigen-binding molecule; methods for delivering the antigen-binding molecule specifically into the cytosol of a target cell; methods of removing, suppressing, or activating a cytosolic antigen in a target cell-specific manner by using the antigen-binding molecule; and pharmaceutical compositions for diagnosing, preventing, or treating a disease in a subject comprising the antigen-binding molecule.

Abstract: Provided are a bispecific antibody and use thereof. The recombinant antibody includes: a CDR Sequence selected from at least one of CD3 antibody variable region CDR sequences: SEQ ID NO: 1 to SEQ ID NO: 6, and B7H6 antibody variable region CDR sequences: SEQ ID NO: 7 to SEQ ID NO: 12; or an amino acid sequence having at least 95% identity thereto. The recombinant antibodies prepared according to the present application can simultaneously target CD3 and B7H6 antigens, and they have a. significantly prolonged half-life, exhibiting a stronger tumor-inhibiting ability than single-target antibodies.

Abstract: A graft copolymer and a preparation method and use thereof. The method for preparing a graft copolymer includes: dissolving an N-ethyl-2-pyrrolidinone-substituted flavan-3-ol (EPSF) and a starch in a polar organic solvent, to obtain a raw material solution; and mixing the raw material solution with ascorbic acid and hydrogen peroxide to obtain a mixture, and subjecting the mixture to a grafting reaction, to obtain the graft copolymer.

Abstract: The present disclosure relates to exopolysaccharides produced by marine bacteria, compositions thereof, the use of aid compositions, and a method for attenuating the virulence of a microbial pathogen infection, either bacterial or viral infections, by inhibiting or reducing colonization of said microbial pathogens onto biological and/or non-biological surfaces.

Abstract: The embodiments described herein pertain to constrained geometry catalyst (CGC)-type titanium catalyst compounds with an amido moiety that features asymmetric substituents that give rise to diastereomerism in new catalysts. Catalyst compounds embodying the present technological advancement are excellent catalysts for variety of transformations including homopolymers of propylene (P), ethylene (E), ethylene-propylene (EP)-copolymers and ethylene-octene (EO) copolymers.

Abstract: A method for producing a fluorine-containing polymer of the present disclosure includes reacting a polymer comprising a unit represented by the following Formula (I) with a fluorine-containing compound represented by the following Formula (II), to obtain a fluorine-containing polymer comprising a unit represented by the following Formula (III).

Abstract: The invention relates to a method for manufacturing thermoplastic poly(vinyl alcohol) derivative in a melt state reaction and a product thereof, wherein the method thermoplastic poly(vinyl alcohol) that has been dried is heated and admixed with an organic acid anhydride that has a catenated carbon structure which ends into a vinyl group, such that a mixture is obtained which is above the melting point of the mixture, thereby causing an ester bond forming condensation reaction in a melt state, wherein at least some of the organic acid anhydride reacts with hydroxyl groups of the thermoplastic poly(vinyl alcohol), such that reaction product is formed which contains carboxylic acid residue and thermoplastic poly(vinyl alcohol) derivative which contains ester bonded pendant chains of which at least some end into vinyl groups. The invention further relates to a method for manufacturing a paper substrate and a product thereof, which contains a primer layer that contains the reaction product.

Abstract: The present invention provides a curable composition comprising (A) at least one (meth)acrylate; (B) at least one diaryliodonium salt; and (C) at least one latent amine catalyst, which can thermally be curable at a temperature of lower than 100° C. and can be also thermally curable and radiation curable. The present curable composition exhibits favorable adhesion strength on various substrates when cured.

Abstract: A film material according to the present disclosure includes an amorphous polymer (A) including a reversible bond which is reversibly dissociated and recombined in response to a temperature change. The polymer (A) has a glass transition temperature of higher than or equal to 40° C. The polymer (A) has a storage elastic modulus of greater than or equal to 0.2 MPa at a temperature higher than the glass transition temperature by 100° C. and a storage elastic modulus of less than or equal to 100 MPa at a temperature higher than the glass transition temperature by 50° C.

Abstract: Disclosed are a curable composition, a cured layer manufactured using the curable composition, a color filter including the cured layer, and a display device including the color filter. The curable composition includes (A) quantum dots; and (B) a curable monomer having a viscosity of less than 6.2 cps and a vapor pressure of 1×10?6 torr to 3×10?3 torr.

Abstract: Proposed are a complex catalyst containing an imine-based ligand for polymerizing a cyclic olefin-based monomer and a method of preparing a cyclic olefin-based polymer using the same. More particularly, proposed are a complex catalyst containing an imine-based ligand for polymerizing a cyclic olefin-based monomer, which can provide the complex catalyst containing the imine-base ligand having high activity in polymerizing the cyclic olefin-based monomer and can prepare a cyclic olefin-based polymer with high activity by polymerizing the cyclic olefin-based monomer in the presence of the complex catalyst containing the imine-based ligand, and a method of preparing a cyclic olefin-based polymer using the same.

Abstract: The present disclosure provides, inter alia, a polymer and oil composition comprising a polymer component, and a synthetic hydrocarbon process oil with a unique branching composition which can be derived from naturally occurring sustainable sources.

Abstract: The present disclosure relates to a method of producing polyethylene. More particularly, the present disclosure relates to a method of producing polyethylene capable of reducing wax produced after polymerization by washing a catalyst used in polymerization of ethylene under optimal conditions.

Abstract: An encapsulant composition for an optical device; comprises an ethylene/alpha-olefin copolymer having high volume resistance and light transmittance. An encapsulant film for an optical device using the same is also provided.

Abstract: Embodiments of the present disclosure are directed towards bicyclic hafnium metallocenes having non-identical ligands and compositions including the bicyclic hafnium metallocenes having non-identical ligands. The bicyclic hafnium metallocene having non-identical ligands is represented by formula (I): ABMX2, where: A is a bicyclic structure; and B is a cyclopentadienyl; M is hafnium; and X is a leaving group, wherein the bicyclic structure comprises a ((C1-C6)alkyl)n-substituted Cp ring and a non-aromatic cyclic structure fused with the ((C1-C6) alkyl)n-substituted Cp ring such that the bicyclic structure includes 7 to 9 ring carbon atoms and wherein subscript n is 1, 2, or 3.

Abstract: Provided is a polyfunctional vinyl aromatic copolymer having reactivity and solubility that can be used for manufacturing a copolymer rubber and a copolymer rubber material having processability, strength and homogeneity obtained therefrom. The polyfunctional vinyl aromatic copolymer includes: 0.5 mol % or more and 40 mol % or less of a structural unit (a) derived from a divinyl aromatic compound and 60 mol % or more and 99.5 mol % or less of a structural unit (b) derived from a monovinyl aromatic compound, in which at least some of the structural units (a) are a crosslinked structural unit (a2) represented by the following Formula (2) and a vinyl-group-containing structural unit (a1) represented by the following Formula (1): in the formulas, R1's independently represent an aromatic hydrocarbon group having 6 to 30 carbon atoms.

Abstract: A multistage polymer is provided, having: acrylate rich stage comprising: (a) structural units of monomer selected from C1-22 alkyl (meth)acrylates and structural units of first carbosiloxane monomer of formula (I); and (b) carbosiloxane rich stage, comprising: structural units of second carbosiloxane monomer of formula (I); wherein a is 0 to 3; wherein d is 0 or 1; wherein R1 is selected from hydrogen, C1-10 alkyl group and aryl group; wherein R2 is selected from hydrogen and C1-10 alkyl group; wherein R8 is —O—Si(CH3)3 group; wherein Y is selected from formula (II), (III) and (IV); wherein R4 and R6 are selected from hydrogen and methyl group; wherein R3 and R5 are a C1-10 alkylene group; wherein R7 is C1-10 alkyl group; wherein b is 0 to 4 and wherein c is 0 or 1; and wherein the first and second carbosiloxane monomer of formula (I) are same or different.

Abstract: The thermal conductivity modifier in the form of hollow particles comprise a shell containing a resin and a hollow portion surrounded by the shell, wherein the shell contains, as the resin, a polymer in which from 80 parts by mass or more of a crosslinkable monomer unit is contained in 100 parts by mass of all monomer units, and wherein, in an immersion test of the thermal conductivity modifier, in which a mixture obtained by adding 0.1 mg of the thermal conductivity modifier to 4 mL of acetone and shaking them for 10 minutes at a shaking rate of 100 rpm, is left to stand for 48 hours in an environment at 25° C., less than 5% by mass of the thermal conductivity modifier submerges in the acetone.

Abstract: Provided is a method for producing a fluorine-containing polymer with little lot-to-lot variation in weight average molecular weight.

Abstract: A method of producing a polymerizable composition including mixing a photochromic compound with one or more polymerizable compounds using an ultrasonic homogenizer.

Abstract: Hollow particles which comprise a shell containing a resin and a hollow portion surrounded by the shell, wherein a void ratio is 50% or more; wherein a volume average particle diameter is 1.0 ?m or more; wherein the shell contains, as the resin, a polymer in which 70 parts by mass to 100 parts by mass of a crosslinkable monomer unit is contained in 100 parts by mass of all monomer units; wherein a thermal expansion coefficient at 80° C. to 200° C. is 10.0×10?5/° C. or less; and wherein, in a hollow particle immersion test in which a mixture obtained by adding 0.1 mg of the hollow particles to 4 mL of acetone and shaking them for 10 minutes at a shaking rate of 100 rpm, is left to stand for 48 hours in an environment at 25° C., less than 10% by mass of the hollow particles submerge in the acetone.